{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:59:26Z","timestamp":1781499566373,"version":"3.54.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the enormous progress made in the treatment of multiple myeloma (MM) with various treatment choices in frontline and relapse settings, treatment of high-risk (HR)MM remains a therapeutic challenge. Definition of HR disease is dynamic and mainly based on cytogenetic assessment showing typical cytogenetic abnormalities. Most recently, the International Myeloma Society and the International Myeloma Working Group published a revision of HR criteria, IMS-IMWG Consensus Genomic Staging. Immediate identification of HRMM at primary diagnosis is crucial to refer the patients to optimal treatment. Emerging data, especially from clinical trials designed explicitly for HR patients, demonstrated that upfront quadruplet treatment followed by consolidation and continuous combination maintenance, including high dose melphalan and autologous stem cell transplantation for patients who qualify, is the current best approach leading to a markedly improved prognosis. The primary treatment goal is the rapid achievement of sustained minimal residual disease\u2013 negative response with treatment continuation beyond to avoid early relapses and evolvement of resistant clones. A distinct subgroup of patients, the so-called functional HR patients, are defined as relapsing between 12 and 18 months despite optimal frontline treatment. The unmet need for effective treatment options in this challenging situation is now partially mitigated by the introduction of B-cell maturation antigen-directed T-cell-engaging immunotherapies. Early data show favorable outcomes, with treatments with chimeric antigen receptor T-cells achieving durable responses.<\/jats:p>","DOI":"10.1182\/hematology.2025000762","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:10:33Z","timestamp":1764943833000},"page":"652-658","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["How to approach the high-risk myeloma from induction through relapse?"],"prefix":"10.1182","volume":"2025","author":[{"given":"Katja C.","family":"Weisel","sequence":"first","affiliation":[{"name":"1 University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schaefers","sequence":"additional","affiliation":[{"name":"1 University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa B.","family":"Leypoldt","sequence":"additional","affiliation":[{"name":"1 University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"2 Mildred Scheel Nachwuchszentrum of the German Cancer Aid at University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2025120616352745700_hem2025000762C1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"key":"2025120616352745700_hem2025000762C2","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","article-title":"Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods","volume":"35","author":"Corre","year":"2021","journal-title":"Leukemia"},{"issue":"26","key":"2025120616352745700_hem2025000762C3","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"29","key":"2025120616352745700_hem2025000762C4","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) Report within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025120616352745700_hem2025000762C5","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO-25-01367","article-title":"Erratum: International Myeloma Society\/International Myeloma Working Group Consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025120616352745700_hem2025000762C6","doi-asserted-by":"crossref","first-page":"e433520","DOI":"10.1200\/EDBK_433520","article-title":"D'Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025120616352745700_hem2025000762C7","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2024-193310","article-title":"Early relapse in patients with newly-diagnosed multiple myeloma: a European Myeloma Network\/harmony alliance analysis including 10843 patients","volume":"144","author":"Mai","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025120616352745700_hem2025000762C8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"2025120616352745700_hem2025000762C9","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2025120616352745700_hem2025000762C10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood.2024027620","article-title":"Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results","volume":"146","author":"Corre","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2025120616352745700_hem2025000762C11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"2025120616352745700_hem2025000762C12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-023-00882-y","article-title":"Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma","volume":"13","author":"Tan","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025120616352745700_hem2025000762C13","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN Nonrandomized Clinical Trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"2025120616352745700_hem2025000762C14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"25","key":"2025120616352745700_hem2025000762C15","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025120616352745700_hem2025000762C16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120616352745700_hem2025000762C17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2023-174841","article-title":"Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T (GC012F\/AZD0120) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma","volume":"142","author":"Du","year":"2023","journal-title":"Blood"},{"key":"2025120616352745700_hem2025000762C18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2024-206003","article-title":"Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) Newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) Trial","volume":"144","author":"Raab","year":"2024","journal-title":"Blood."},{"issue":"6","key":"2025120616352745700_hem2025000762C19","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025120616352745700_hem2025000762C20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120616352745700_hem2025000762C21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025120616352745700_hem2025000762C22","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S2152-2650(24)01894-9","article-title":"OA-53 Isa-KRd in high-risk newly diagnosed multiple myeloma \u2013 4-year-follow-up from the GMMG- CONCEPT trial","volume":"24","author":"Leypoldt","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"1","key":"2025120616352745700_hem2025000762C23","first-page":"63","article-title":"Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG- CONCEPT trial","volume":"11","author":"Leypoldt","year":"2025","journal-title":"Cardiooncology"},{"key":"2025120616352745700_hem2025000762C24","doi-asserted-by":"crossref","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): first-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial [abstract S209; oral presentation]","author":"Leypoldt","DOI":"10.1200\/JCO.2025.43.16_suppl.7509"},{"issue":"23","key":"2025120616352745700_hem2025000762C25","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025120616352745700_hem2025000762C26","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025120616352745700_hem2025000762C27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2025120616352745700_hem2025000762C28","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"2025120616352745700_hem2025000762C29","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2025120616352745700_hem2025000762C30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"M-A","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"2025120616352745700_hem2025000762C31","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025120616352745700_hem2025000762C32","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"2025120616352745700_hem2025000762C33","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"2025120616352745700_hem2025000762C34","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"2025120616352745700_hem2025000762C35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2019-129431","article-title":"Real-world outcome for newly diagnosed patients with functional high-risk myeloma - a myeloma and related diseases registry analysis","volume":"134","author":"Spencer","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2025120616352745700_hem2025000762C36","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"key":"2025120616352745700_hem2025000762C37","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2025.43.16_suppl.7501","article-title":"Subcutaneous daratumumab (Dara) + bortezomib\/lenalidomide\/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial","volume":"43","author":"Moreau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025120616352745700_hem2025000762C38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2025120616352745700_hem2025000762C39","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2024.42.16_suppl.7504","article-title":"Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis","volume":"42","author":"Costa","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025120616352745700_hem2025000762C40","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(24)01948-7","article-title":"P-045 Idecabtagene vicleucel (ide-cel) in patients (pts) with clinical high-risk early relapse multiple myeloma (mm) without front-line (1L) autologous stem cell transplantation (ASCT): KarMMA-2 Cohort 2B","author":"Leleu","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia."},{"issue":"18","key":"2025120616352745700_hem2025000762C41","first-page":"1722","article-title":"Teclistamab in relapsed or refractory multiple myeloma. Reply","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2025120616352745700_hem2025000762C42","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2025120616352745700_hem2025000762C43","doi-asserted-by":"crossref","first-page":"e20017","DOI":"10.1200\/JCO.2023.41.16_suppl.e20017","article-title":"Efficacy and safety of elranatamab in patients with high-risk relapsed\/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3","volume":"41","author":"Larson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025120616352745700_hem2025000762C44","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025120616352745700_hem2025000762C45","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"2025120616352745700_hem2025000762C46","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025120616352745700_hem2025000762C47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-024-01088-6","article-title":"Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN","volume":"14","author":"Chari","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"2025120616352745700_hem2025000762C48","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 Trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120616352745700_hem2025000762C49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025120616352745700_hem2025000762C50","doi-asserted-by":"crossref","first-page":"e046225","DOI":"10.1136\/bmjopen-2020-046225","article-title":"MUKnineOPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-ri","volume":"11","author":"Brown","year":"2021","journal-title":"BMJ Open"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/652\/2469845\/652weisel.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/652\/2469845\/652weisel.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:35:39Z","timestamp":1765056939000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/652\/556904\/How-to-approach-the-high-risk-myeloma-from"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000762","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}